Paradoxically, Ziebolz D. et al. found that the DMARDs that most negatively affect the state of periodontium in RA patients are the combination of MTX and anti-TNF-α, compared to LFN in monotherapy and to the combination of MTX and rituximab [81]. Here, TNF is linked to rheumatoid arthritis.